About: LDL-C or apoB as the best target for reducing coronary heart disease: should apoB be implemented into clinical practice?

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: LDL-C or apoB as the best target for reducing coronary heart disease: should apoB be implemented into clinical practice? Goto Sponge NotDistinct Permalink

An Entity of Type : http://linked.opendata.cz/ontology/domain/vavai/Vysledek, within Data Space : linked.opendata.cz associated with source document(s)

Attributes	Values
rdf:type	skos:Concept http://linked.opendata.cz/ontology/domain/vavai/Vysledek
Description	LDL-C is considered to be the major lipid risk factor and the main target of lipid-lowering therapy. Nevertheless, as all potentially atherogenic lipoprotein particles contain only one molecule of apoB and various amounts of cholesterol, apoB is a better marker of atherogenic particle numbers. Many laboratory, prospective and interventional studies have proved that apoB is a better indicator of cardiovascular risk than LDL-C. Statins lower LDL-C and non-HDL-C more (and to lower population percentile levels) than apoB. As a result, many patients treated with statins to achieve LDL-C and non-HDL-C targets remain at high risk owing to high levels of apoB, especially subjects with the prevalence of small dense LDL. With the worldwide increasing prevalence of obesity and metabolic syndrome, the issue of appropriate risk markers and treatment goals is even more important. LDL-C is considered to be the major lipid risk factor and the main target of lipid-lowering therapy. Nevertheless, as all potentially atherogenic lipoprotein particles contain only one molecule of apoB and various amounts of cholesterol, apoB is a better marker of atherogenic particle numbers. Many laboratory, prospective and interventional studies have proved that apoB is a better indicator of cardiovascular risk than LDL-C. Statins lower LDL-C and non-HDL-C more (and to lower population percentile levels) than apoB. As a result, many patients treated with statins to achieve LDL-C and non-HDL-C targets remain at high risk owing to high levels of apoB, especially subjects with the prevalence of small dense LDL. With the worldwide increasing prevalence of obesity and metabolic syndrome, the issue of appropriate risk markers and treatment goals is even more important. (en)
Title	LDL-C or apoB as the best target for reducing coronary heart disease: should apoB be implemented into clinical practice? LDL-C or apoB as the best target for reducing coronary heart disease: should apoB be implemented into clinical practice? (en)
skos:prefLabel	LDL-C or apoB as the best target for reducing coronary heart disease: should apoB be implemented into clinical practice? LDL-C or apoB as the best target for reducing coronary heart disease: should apoB be implemented into clinical practice? (en)
skos:notation	RIV/61989592:15110/11:10224615!RIV12-MZ0-15110___
http://linked.open...avai/riv/aktivita	P
http://linked.open...avai/riv/aktivity	P(NS10284)
http://linked.open...iv/cisloPeriodika	1
http://linked.open...vai/riv/dodaniDat	2012
http://linked.open...aciTvurceVysledku	VAVERKOVÁ, Helena
http://linked.open.../riv/druhVysledku	J - Článek v odborném periodiku
http://linked.open...iv/duvernostUdaju	S - Úplné a pravdivé údaje nepodléhající ochraně podle zvláštních právních předpisů
http://linked.open...titaPredkladatele	Univerzita Palackého v Olomouci / Lékařská fakulta
http://linked.open...dnocenehoVysledku	209082
http://linked.open...ai/riv/idVysledku	RIV/61989592:15110/11:10224615
http://linked.open...riv/jazykVysledku	eng - angličtina
http://linked.open.../riv/klicovaSlova	non-HDL-C; lipid lowering therapy; LDL-C; guidelines; coronary heart disease; apoB (en)
http://linked.open.../riv/klicoveSlovo	LDL-C apoB lipid lowering therapy non-HDL-C guidelines coronary heart disease
http://linked.open...odStatuVydavatele	GB - Spojené království Velké Británie a Severního Irska
http://linked.open...ontrolniKodProRIV	[CEB4342A694D]
http://linked.open...i/riv/nazevZdroje	Clinical Lipidology
http://linked.open...in/vavai/riv/obor	FB
http://linked.open...ichTvurcuVysledku	1 (xsd:int)
http://linked.open...cetTvurcuVysledku	1 (xsd:int)
http://linked.open...vavai/riv/projekt	Dyslipidemia and prehypertension - association of dyslipidemic phenotypes with prevalence of prehypertension. Association of prehypertension with markers of insulin resistance, inflammation, endothelial dysfunction and subclinical atherosclerosis.
http://linked.open...UplatneniVysledku	2011
http://linked.open...v/svazekPeriodika	6
http://linked.open...iv/tvurceVysledku	VAVERKOVÁ, Helena
issn	1758-4299
number of pages	14 (xsd:int)
http://localhost/t...ganizacniJednotka	15110

Faceted Search & Find service v1.16.118 as of Jun 21 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 58 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software